Cogent Biosciences, Inc. (COGT)
34.69
-0.31
(-0.89%)
USD |
NASDAQ |
Sep 01, 16:00
34.69
0.00 (0.00%)
After-Hours: 16:13
Cogent Biosciences Research and Development Expense (Annual) : 265.16M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 265.16M |
| December 31, 2024 | 228.26M |
| December 31, 2023 | 170.17M |
| December 31, 2022 | 115.75M |
| December 31, 2021 | 55.77M |
| December 31, 2020 | 25.74M |
| Date | Value |
|---|---|
| December 31, 2019 | 43.71M |
| December 31, 2018 | 38.28M |
| December 31, 2017 | 29.83M |
| December 31, 2016 | 21.99M |
| December 31, 2015 | 6.852M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Apogee Therapeutics, Inc. | 214.42M |
| Erasca, Inc. | 92.85M |
| Moderna, Inc. | 2.917B |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |